Logo En IconLogo Mark IconIcelandic Intellectual Property Office
Plus Black IconMortgagePlus Black IconLicense

SPC501

Erdafitinib eða lyfjafræðilega viðunandi salt þar af eða lausnarsamband þar af / Erdafitinib or a pharmaceutically acceptable salt thereof or a solvate thereof

  • Status:
    Veitt
  • Application date:
    14.2.2025
  • Application published:
    15.3.2025
  • Grant published:
    15.12.2025
  • Max expiry date:
    27.4.2036
  • Medicine name:
    Balversa
  • Medicine for children:
    No

Timeline

Today
14.2.2025Application
15.3.2025Publication
15.12.2025Registration
27.4.2036Expires

Marketing license

  • IS authorization number:
    EU/1/24/1841
  • Date:
    12.9.2024
  • Foreign authorization number:
    EU/1/24/1841
  • Date:
    22.8.2024

Owner

  • Name:
    Astex Therapeutics Limited
  • Address:
    436 Cambridge Science Park Milton Road, Cambridge Cambridgeshire CB4 0QA GB

Agent

  • Name:
    Árnason Faktor ehf.
  • Address:
    Guðríðarstíg 2-4, 113 Reykjavík

Patent

Deadlines

TypeDeadline until

Type: Frestur til að fara yfir drög að vottorði

Deadline until: 22.11.2025

Upload documents